Insider Buying: GSK (LON:GSK) Insider Buys £40,653.38 in Stock

GSK plc (LON:GSK) insider Jeannie Lee purchased 802 shares of GSK stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of GBX 5,069 per share, for a total transaction of £40,653.38.

GSK Trading Up 1.8%

LON:GSK traded up GBX 35.50 during mid-day trading on Tuesday, hitting GBX 1,960. 27,888,139 shares of the company’s stock were exchanged, compared to its average volume of 8,764,782. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. GSK plc has a fifty-two week low of GBX 1,288.61 and a fifty-two week high of GBX 2,282. The company has a 50 day simple moving average of GBX 1,955.63 and a 200-day simple moving average of GBX 1,966.35. The firm has a market capitalization of £78.60 billion, a P/E ratio of 13.79, a PEG ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The company had revenue of GBX 762.90 billion for the quarter. As a group, research analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GSK shares. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,900 target price on shares of GSK in a research report on Monday, June 8th. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Finally, Citigroup decreased their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus price target of GBX 2,034.29.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.